Thermo Fisher Scientific Inc. reported strong Q4 2025 earnings with revenue of approximately $12.2 billion and a 7% year-over-year growth, despite its stock facing a 12% dip over the past three months. Analysts have responded positively, lifting price targets while maintaining 'Buy' ratings, indicating confidence in the company's long-term prospects. Looking ahead, Thermo Fisher is guiding for revenue growth between 4% to 6% for 2026 and aims to enhance its market presence through a partnership with Datavant to better integrate real-world data into clinical research.
“Thermo Fisher · has market cap · $195.4 billion · true”
“Thermo Fisher · has annual sales growth · 2% · over the last two years”
“Thermo Fisher · is trading at · $514.55 per share · true”
“Market leaders · include · Illumina, Abbott Laboratories, and Thermo Fisher Scientific”
“Thermo Fisher · has a market cap of · $192 billion · true”
“Thermo Fisher · annual sales growth over the last two years is · 2% · true”
“Thermo Fisher · trades at · $508 per share · true”
“Thermo Fisher · has a market cap of · Thermo Fisher · $195.4 billion”
“Thermo Fisher Scientific Inc. (NYSE:TMO) · is · one of the best strong buy healthcare stocks to invest in”
“Thermo Fisher Scientific Inc. (NYSE:TMO) · reported · fiscal Q4 revenue · $12.21 billion”
“Thermo Fisher Scientific Inc. (NYSE:TMO) · reported · fiscal Q4 revenue growth · 7%”
“Thermo Fisher Scientific Inc. (NYSE:TMO) · reported · GAAP diluted earnings per share for the quarter · $5.21”
